We have located links that may give you full text access.
Genetic and Epigenetic Associations with Pre-COPD Lung Function Trajectories.
American Journal of Respiratory and Critical Care Medicine 2023 August 24
RATIONALE: Understanding the pathobiology of life-course lung function trajectories that progress to COPD, especially with a rapidly declining phenotype, can inform preventive interventions. Genetic and environmental interactions may contribute to these high-risk trajectories through epigenetic variation Objectives: A pilot to broadly characterise genetic and epigenetic contributions to high-risk trajectories in middle-aged people.
METHODS: Blood genome-wide genetic and epigenetic markers were profiled in 160 donors at 45 years of age from the Tasmanian Longitudinal Health Study (TAHS). High-risk subjects were selected from three previously published lifetime FEV1 trajectories that together accounted for 75% of COPD prevalence at age 53 years, and were matched to persistently high trajectory controls. Differentially methylated regions and epigenetic age acceleration differences between the groups were examined. The impact of co-morbidities and genetic variants on the observed epigenetic associations were investigated.
RESULTS: Subjects from the high risk FEV1 trajectories exhibited 55 novel regions of epigenetic divergence (FDR < 0.05) at genes related to cellular adhesion and epithelial biology. Current asthma or COPD co-morbidities partially explained these changes. Allelic variation at Major Histocompatibility Complex (MHC) and other loci was associated with epigenetic changes and linked to lung specific gene expression signatures and COPD/lung function traits in GWAS. Epigenetic age acceleration was independently associated with high-risk trajectories, which was most pronounced in the rapid decline one.
CONCLUSIONS: High risk trajectories that progress to COPD exhibited genetic and epigenetic associations at epithelial and histocompatibility genes as well as accelerated epigenetic ageing.
METHODS: Blood genome-wide genetic and epigenetic markers were profiled in 160 donors at 45 years of age from the Tasmanian Longitudinal Health Study (TAHS). High-risk subjects were selected from three previously published lifetime FEV1 trajectories that together accounted for 75% of COPD prevalence at age 53 years, and were matched to persistently high trajectory controls. Differentially methylated regions and epigenetic age acceleration differences between the groups were examined. The impact of co-morbidities and genetic variants on the observed epigenetic associations were investigated.
RESULTS: Subjects from the high risk FEV1 trajectories exhibited 55 novel regions of epigenetic divergence (FDR < 0.05) at genes related to cellular adhesion and epithelial biology. Current asthma or COPD co-morbidities partially explained these changes. Allelic variation at Major Histocompatibility Complex (MHC) and other loci was associated with epigenetic changes and linked to lung specific gene expression signatures and COPD/lung function traits in GWAS. Epigenetic age acceleration was independently associated with high-risk trajectories, which was most pronounced in the rapid decline one.
CONCLUSIONS: High risk trajectories that progress to COPD exhibited genetic and epigenetic associations at epithelial and histocompatibility genes as well as accelerated epigenetic ageing.
Full text links
Related Resources
Trending Papers
Revascularization Strategy in Myocardial Infarction with Multivessel Disease.Journal of Clinical Medicine 2024 March 27
Intravenous infusion of dexmedetomidine during the surgery to prevent postoperative delirium and postoperative cognitive dysfunction undergoing non-cardiac surgery: a meta-analysis of randomized controlled trials.European Journal of Medical Research 2024 April 19
The Tricuspid Valve: A Review of Pathology, Imaging, and Current Treatment Options: A Scientific Statement From the American Heart Association.Circulation 2024 April 26
Consensus Statement on Vitamin D Status Assessment and Supplementation: Whys, Whens, and Hows.Endocrine Reviews 2024 April 28
Management of Diverticulitis: A Review.JAMA Surgery 2024 April 18
Interstitial Lung Disease: A Review.JAMA 2024 April 23
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app